Clinical Trial Detail

NCT ID NCT04143711
Title Study of DF1001 in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Dragonfly Therapeutics
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Advanced Solid Tumor

breast cancer

Therapies

DF1001

DF1001 + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST